Clinical Trial Update: Iressa 2nd Line Phase III Study in Japan [Phase 3]

View source ↗

Summary

A Phase 3 study of Iressa (gefitinib) as second-line therapy for non-small cell lung cancer in Japan has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (gefitinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: COMPLETED